T2 Biosystems Announces FDA 510(k) Submission to Expand Use of the FDA-Cleared T2Candida Panel to Include Pediatric Testing
LEXINGTON, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) — T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that it has submitted a 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) to expand the use of its FDA-cleared T2Candida® Panel to include pediatric testing.
Related news for (TTOO)
- T2 Biosystems Announces Preliminary Fourth Quarter and Full Year 2024 Financial Results
- T2 Biosystems Announces Sale of Four T2Dx Instruments to Existing European Distributor
- T2 Biosystems Achieves Key Milestone with 250,000th Novel Sepsis Test Shipped Globally
- T2 Biosystems Announces Extension of Multi-Year Capital Equipment Supplier Agreement with Vizient, Inc.
- T2 Biosystems Announces Plans to License its Proprietary Technology to Expand its Leadership in Direct-From-Whole-Blood Detection of Sepsis-Causing Pathogens